Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis

AK Weidemann, AA Crawshaw, E Byrne… - Clinical, cosmetic and …, 2013 - Taylor & Francis
Psoriasis is a common inflammatory autoimmune condition in which environmental factors
and genetic predisposition contribute to the development of disease in susceptible …

Gastrointestinal stromal tumors: current management

PWT Pisters, SR Patel - Journal of surgical oncology, 2010 - Wiley Online Library
Herein, we review the current management of localized and advanced gastrointestinal
stromal tumors (GISTs). Although surgery remains the standard of care for patients with …

[HTML][HTML] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

AW Tolcher, LJ Appleman, GI Shapiro, AC Mita… - Cancer chemotherapy …, 2011 - Springer
Purpose To characterize the cardiovascular profile of sorafenib, a multitargeted kinase
inhibitor, in patients with advanced cancer. Methods Fifty-three patients with advanced …

Tolerability of first-line therapy for metastatic renal cell carcinoma

C Porta, C Szczylik - Cancer Treatment Reviews, 2009 - Elsevier
The treatment options for metastatic renal cell carcinoma have expanded rapidly over the
past 3 years, with four new agents available and others in late-stage development. This has …

Sunitinib-induced congestive heart failure in a patient with gastrointestinal stromal tumor

WB Kridis, S Masmoudi… - Archives of Iranian …, 2022 - search.proquest.com
Common cardiovascular toxicities of sunitinib mainly include hypertension, QT prolongation,
left ventricular dysfunction (LVD) and less frequently, congestive heart failure (CHF). Here …

[PDF][PDF] Tyrosine kinase inhibitors of VEGF receptors: clinical issues and unanswered questions

H Van Cruijsen, AA Van der Veldt, K Hoekman - Front Biosci, 2008 - research.vumc.nl
The number of VEGFR tyrosine kinase inhibitors (TKIs) used as an anti-cancer agent is
rapidly increasing, but several issues in clinical practice remain to be elucidated. VEGFR …

A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer

RL Jones, JC Bendell, DC Smith, K Diefenbach… - Cancer chemotherapy …, 2015 - Springer
Purpose To characterize the cardiovascular safety profile of regorafenib in patients with
advanced cancer. Methods Patients received regorafenib 160 mg/day for 21 days followed …

Response to sorafenib after sunitinibinduced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature

MKK Wong, A Jarkowski III - Pharmacotherapy: The Journal of …, 2009 - Wiley Online Library
Cardiotoxicity is an emerging concern with a new class of drugs known as targeted agents,
which include trastuzumab and sunitinib. Sunitinib is a small molecule that inhibits multiple …

胃肠间质瘤复发和转移的治疗

钱红纲, 郝纯毅 - 中国实用外科杂志, 2010 - cqvip.com
胃肠间质瘤复发和转移的治疗-[维普官方网站]-www.cqvip.com-维普网 我的维普 购物车 充值
客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 学者空间 | 学术机构 …

Chemotherapy-induced cardiomyopathy

SW Yusuf, NA Ilias-Khan, JB Durand - Expert review of …, 2011 - Taylor & Francis
Improvement in cancer therapy has led to an increasing number of cancer survivors, some of
whom may suffer from the cardiotoxic effects of chemotherapy. Cardiomyopathy can occur …